Dr. Nagourney's Blog


Informative articles sent right to your inbox. Subscribe to Dr. Nagourney's blog today.

Triple Negative Breast Cancer - Worse or Just Different?
By Robert A. Nagourney, MD
The term “triple negative breast cancer” (TNBC) is applied to a subtype of breast cancers that do not express the estrogen or progesterone receptors. Nor do they overexpress the HER2 gene. This disease constitutes 15 – 20 percent of all breast...
What Exactly are the Targets of Targeted Therapy?
By Robert A. Nagourney, MD
The term “targeted therapy” has entered common parlance. Like personalized medicine, targeted therapy is a generic description...
Activity of MEK/ERK and PI3K/mTOR Inhibitors Explored
By Robert A. Nagourney, MD
The Sunday, April 3, 2011, experimental and molecular therapeutics session at the AACR 102nd annual meeting included our...
Targeted Therapies — The Next Chapter
By Robert A. Nagourney, MD
Within this blog, we have intermittently reviewed the concept of targeted therapies. To reiterate, these are classes of drugs...
New Drugs Are Not Always Better Drugs - Renal Cell Carcinoma Success
By Robert A. Nagourney, MD
The most common form of renal (kidney) carcinoma is the clear cell variant. These tumors are driven by mutations in the VHL...

browse by topic

Select A topic

View All Topics

most popular articles

patient story

How We Helped David Hanbidge

"I'll never forget the day when the doctor took my wife and me to a small back office and told us the horrible news…I had the very worst kind of lung cancer..."   Read about how we helped David.